laboratori corp america hold lh nyse qqq
updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
valuat growth profit
methodolog valu compani
particip highli attract duopoli offer bright
prospect healthcar move toward reform payment model
even though hospit still domin billion diagnost
market labcorp carv signific slice pie
serial acquisit addit covanc drug-develop
expertis offer labcorp avenu monet larg patient
labcorp continu acquir smaller rival strategi
paid firm firm grow anticip cost
structur becom even competit attract
larg managed-car payer increas
importantli labcorp single-mindedli pursu greater
effici translat abil reduc cost
quickli reimburs cut come pike firm
invest greater autom system decreas
number employe involv sort run test
labcorp also put signific resourc behind beef
inform technolog capabl result physician
easili access test inform time manner
patient schedul blood draw increas conveni
admir manag team consist focus
strategi long term expect labcorp
invest today reap reward futur year
labcorp take advantag long-term secular trend
bode well diagnost industri prolifer
new test grow new diseas marker genet mutat
pharmacogenom
implic discov new
reimburs model inspir healthcar reform lead
doctor hospit send test lower-cost produc
like labcorp though util hit soft
period thank recessionari condit volum turn corner
financi stress eas new insur join
roll labcorp also sought enhanc abil find
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
nation second-largest
laboratori corpor america
independ clinic laboratori roughli independ lab
market compani oper patient-servic center
offer broad rang clinic lab test rang routin blood
urin screen complex oncolog genom test addit
covanc labcorp also sizabl footprint global contract
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
labcorp cap strong perform
fourth quarter modestli exceed expect
weve rais fair valu estim per share
weve bump project higher growth
drug develop segment well
profit thank new cost effici account
slightli half increas valuat
half increas driven firm new lower
effect tax rate remain confid firm narrow
econom moat continu think labcorp weather
pama-rel cut medicar clinic lab fee
schedul midterm
even without top-lin boost acquisit
labcorp deliv respect underli growth
quarterli organ volum growth clock
consider stronger quest though
revenu per requisit soft addit chiltern
drug develop segment shore firm
presenc small medium size biopharma
area pleas see drug develop seen
four consecut quarter growth backlog net
industri lawsuit depart
human servic challeng medicar clf rate
set could take month resolv think
lab industri offer compel argument
process set rate particularli applic lab
defin cut alreadi implement
long thought rate cut would
longer term caus small independ hospital-
quest
labcorp consid difficulti hospit
isol lab profit could take number
quarter see flow test volum larg
shift volum
valuat growth profit feb
rais fair valu estim per share
half increas driven
optimist project drug develop busi
sustain four consecut quarter
growth addit chiltern give labcorp greater
footprint small medium size biopharma area
greater-than-expect impact tax cut labcorp
effect rate account half increas
continu expect new medicar clinic lab fee
schedul adjust greater impact
taper origin
estim effect tax rate labcorp
actual rate substanti lower estim
top-lin growth averag annual follow
five year near term anticip volum growth
solidifi thank increas healthcar util
gradual transit bundl capit
keep long-term trend anticip
increas growth genom esoter test compar
routin test labcorp done good job
launch new complex test lead us believ
annual esoter test volum outpac market growth
also think special test carri higher
price tag routin counterpart result averag
annual price increas long term
off-set reimburs pressur routin
test still make bulk labcorp test mix
think labcorp recent evolv
invest beacon lb enlighten health
covanc put firm strong posit take
advantag emerg opportun longer term
demonstr valu refer lab add beyond
deliveri reliabl accur test data anticip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
leverag translat gain
bearish scenario project sluggish volum growth
aca-rel fund ignor washington
number uninsur patient rise drug
develop segment fail reach histor growth level
also bake increas bad debt expens
estim oper margin fall basi
point next five year thank weak volum
tight price pressur bear labcorp case put
fair valu estim per share
labcorp narrow moat base vast nation
infrastructur translat consider scale
advantag smaller region lab independ
diagnost test industri primari test lab
patient-servic center across unit state
labcorp abl run test specimen day
substanti lower cost hospit
doctor offic smaller independ lab popul
market labcorp abil accommod higher
throughput extens use autom afford
firm much lower cost structur -- significantli lower
hospit smaller independ lab
advantag also mean labcorp model character
substanti oper leverag oper leverag
work firm wake recess
healthcar util fell howev util
return growth labcorp also benefit though
addit cro busi pressur margin
although price ration recent past
potenti price competit keep us award
payer would typic rather negoti largest
refer lab includ labcorp provid best
acquisit add approxim per year total
think labcorp make
adjust oper
margin -- tune basi point -- time
base sole averag volatil cash flow
labcorp underli diagnost busi would rate
firm uncertainti medium howev assumpt
lower corpor tax rate base-cas bull
scenario along conserv project
fail tax reform bear case widen
uncertainti high
bull case valu share scenario
assum robust volum gain stronger-than-expect
price gain come implement pama rate
greater-than-anticip revenu synergi
combin labcorp patient databas
covanc clinic trial busi result adjust
annual top-lin growth higher
throughput assum labcorp enjoy greater oper
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
geograph coverag insur base instead
cobbl togeth market-by-market coverag
multipl smaller region lab final labcorp scale
reach make attract partner research
invent variou diagnost test distribut
channel sell test labcorp recent
invest dedic lab focus companion
diagnost anoth indic firm think
creativ close partner
entiti healthcar arena
think addit covanc solidifi labcorp
narrow moat -- previous award covanc narrow
moat right contract research organ
moatiest part busi late-stag clinic
trial global infrastructur critic easili
replic legaci covanc busi also benefit
intang asset includ expertis local countri
cultur regulatori agenc chang regul
research design data analyt knowledg key diseas
state close relationship pharmaceut
see labcorp moat trend posit think labcorp
particularli well-posit take advantag
long-term opportun emerg wake
healthcar reform evolut volume-bas
value-bas reimburs payer assess valu
link chain patient diagnosi
treatment simultan widespread adopt
new digit tool manipul analyz patient data
two factor set stage diagnost
compani demonstr valu diagnost
test -- specif much time money save --
captur valu tradit gone
therapeut agent end-stag treatment new
avenu growth diagnost compani exist
healthcar reform push
see new growth prospect horizon
diagnost compani abil ultim capit
depend well develop capabl beyond
current core compet logist lab qualiti
must develop new expertis data collect
integr well informat point think
labcorp pull ahead quest prepar
first labcorp alreadi laid groundwork
integr inform technolog platform --
first step toward possibl aggreg test data
second labcorp alreadi dip toe water
come informat challeng
measur cost save diagnost particular
think firm experi demonstr result
small-scal kidney stone manag chronic
kidney diseas monitor program give labcorp leg
competit futur expect see labcorp
target key diseas area early-detect
treatment monitor program could implement
provid cost save addit covanc late-stag
trial expertis boost labcorp abil conduct
third applaud labcorp savvi move launch new
enlighten genom unit firm initi
address immens potenti next-gener
sequenc although yet reach point
routin sequenc take place patient
question technolog alreadi shape
realm oncolog see applic heart
diseas central nervou system neurolog labcorp
busi build capabl area new
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
geneticist staff well specialist analyt
valu amass proprietari test
patient data labcorp alreadi detect trend
enlighten health busi put firm strong
posit key owner data line
final acquisit covanc expertis data
analyt clinic trial give labcorp big boost
capabl anticip labcorp find new
applic covanc compet tie diagnost
measur therapi patient outcom cost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
olabcorp beacon softwar make easier
physician get share test result potenti
increas sticki practition relationship
oth complex labor-intens esoter test
reimburs higher rate often outsourc
hospit independ lab labcorp funnel
resourc broaden menu complex esoter
test help maintain healthi margin
olabcorp abl keep less profit
capit managed-car contract minimum
account diagnost revenu
oit possibl industri lawsuit
human servic fail market-bas
rate medicar clinic lab fee schedul
olabcorp need analyt expertis covanc
would diminish labcorp retain
oit could take longer anticip bundl
payment becom norm provid
case increas volum ensu oper
leverag could five year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
acquisit covanc increas labcorp debt
leverag substanti fund acquisit earli
labcorp borrow five-year term loan may
prepaid without penalti billion new senior
unsecur note matur
end decemb labcorp debt stood
billion time ebitda time prior
acquisit howev end debt/ebitda
fallen time firm debt tick time
labcorp yet reach target ratio
time longer term comparison quest aim
low long run even slightli higher
higher cash level may keep net leverag
roughli line even slightli lower quest
long run addit million cash held
balanc sheet end estim
labcorp abl gener billion averag
annual free cash flow next five year
plenti help firm manag debt oblig
intern mean
base averag volatil cash flow labcorp
underli diagnost busi rate firm
uncertainti medium despit mani long-term clinic
undercurr favor labcorp see
potenti near-term bumpi sever great
recess spur declin patient volum across
specialti consum delay seek
healthcar especi nonacut nonsymptomat
condit seen gradual resumpt growth
patient traffic unfavor macro condit aris
labcorp volum could drop key measur
afford act dismantl could lead
less volum higher bad debt expens chang
reimburs penetr high-deduct plan
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
substanti cost-shar measur also left
patient larger out-of-pocket burden could
becom perenni drag growth diagnost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
repres date owner name posit common share held report holder issuer
assign standard stewardship rate labcorp david
king took role ceo earli follow
retir thoma mahon held posit
nearli decad brief transit period king also
took titl chairman think king prior
experi labcorp good foundat
core diagnost busi impress
king navig compani
increasingli competit industri landscap mention
steep recession-l downturn volum king previou
experi labcorp corpor plan strateg
develop function also advantag
perspect especi consid firm on-going
relianc acquisit smaller lab
opportun arisen adjac area howev
note labcorp compens polici rel
gener king earn million
past three year
one hand appreci king vision
understand healthcar system lurch
lab need adapt potenti move new line
busi think acquisit covanc reflect
king view simpli gener data longer enough
captur valu healthcar futur healthcar
competitor also compet basi proprietari
ownership data well abil translat
data usabl medic knowledg hand
think king tendenc appli great pressur
execut team could lead greater turnov may
prevent firm realiz potenti emerg
share
fund
share
fund
new jersey divis pension benefit
overal appreci manag execut
year firm maintain great major
contract payer provid custom even
rack new client sizabl empir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
cross shield plan new york exclus
contract negoti rais
eyebrow time concern unfavor
price labcorp born importantli like
labcorp capital-alloc decis particular firm
exercis financi disciplin acquisit strategi
acquisit accret shortli close
firm avoid write goodwil although
labcorp pay dividend manag funnel
return sharehold form share buyback
applaud firm acceler repurchas share
trade discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
labcorp cap strong perform
fourth quarter modestli exceed expect
weve rais fair valu estim per share
weve bump project higher growth
drug develop segment well
profit thank new cost effici account
slightli half increas valuat
half increas driven firm new lower
effect tax rate remain confid firm narrow
econom moat continu think labcorp weather
pama-rel cut medicar clinic lab fee
schedul midterm
even without top-lin boost acquisit
labcorp deliv respect underli growth
quarterli organ volum growth clock
consider stronger quest though
revenu per requisit soft addit chiltern
drug develop segment shore firm
presenc small medium size biopharma
area pleas see drug develop seen
four consecut quarter growth backlog net
industri lawsuit depart
human servic challeng medicar clf rate
set could take month resolv think
lab industri offer compel argument
process set rate particularli applic lab
defin cut alreadi implement
long thought rate cut would
longer term caus small independ hospital-
quest
labcorp consid difficulti hospit
isol lab profit could take number
shift volum
quarter see flow test volum larg
chang fve oct
acquisit diagnost lab clinic trial
segment year-to-d result labcorp close match
project full year leav fair valu
estim unchang even organ basi
quarterli volum growth respect
strongest gain weve seen past month revenu
per requisit came slightli lower
recent quarter howev continu run consider
higher rival quest diagnost like due
higher mix esoter test labcorp view
labcorp narrow econom moat hasnt chang
longer term reimburs pressur ratchet
diagnost expect labcorp benefit
increment volum divert hospital-bas lab
near-term impact propos pama-rel
manag hesit specul expect
cut affect margin although bake
medicar reduct start cut didnt move
valuat materi impact soften
labcorp diversif clinic trial busi
public comment period propos clf
end medic industri associ appeal
rethink univers lab propos
rate base think may chanc
cut implement propos jan
one hand new administr seema verma may
much concern potenti fallout would hurt
access patient institut care non-dens
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
origin absenc inform test code
adjust actual privat payer payment
inform project chang medicar
clf would knock basi point labcorp total
revenu annual addit inform test
code magnitud payment adjust
fine-tun assumpt expect total
revenu declin averag basi point annual
greatest impact first two year due
adjust test commonli
conduct much depend assumpt
labcorp exposur first test code
revis compani disclos littl
inform test volum mix
point think chanc delay
implement low technic
obstacl stand way roll new
payment howev think chanc final
reimburs rate could revis upward especi
hospit vocal concern payment
adjust would hit smaller lab chin
midterm expect either funnel
test volum larg independ close door
altogeth ultim favor labcorp
long term
geographi smaller lab like close
signific pressur legisl
magnitud cut could see delay
revisit process
despit near-term price pressur continu
believ pama-l reduct clf caus
hospital-bas lab smaller independ divert test
volum lower cost produc labcorp base
manag comment quest labcorp
sign signific uptick sale closur
lab surpris uncommon
hospital-bas lab smaller independ
robust inform technolog system place ascertain
profit differ lab program even profit
type lab test specul concret impact
lower reimburs may hit home smaller
lab actual experi lower payment
expect smaller competitor grappl
declin reimburs next coupl year
well see outsourc volum labcorp
quest sell larger lab shut door
complet two-to-f year time frame
re-examin impact propos reimburs
adjust medicar clinic lab fee schedul
hold steadi fair valu estim
labcorp chang assumpt
materi shift valuat although propos
reimburs cut larger wed anticip
labcorp rel shield impact thank
addit drug trial busi continu think
labcorp narrow econom moat intact
immens volum labcorp remain one best
posit diagnost lab absorb type payment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
laboratori corp america hold lh nyse qqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
